Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.
Doravirine was approved for medical use in the United States in August 2018.[7]
Doravirine is available in fixed-dose combinations with other HIV drugs such as doravirine/lamivudine/tenofovir (sold under the brand name Delstrigo).[8]
References
- ^ a b "Pifeltro- doravirine tablet, film coated". DailyMed. 10 October 2019. Retrieved 22 September 2020.
- ^ Collins S, Horn T. "The Antiretroviral Pipeline" (PDF). Pipeline Report. p. 10. Archived from the original (PDF) on 11 March 2016. Retrieved 6 December 2015.
- ^ "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : PIFELTRO" (PDF). Pdf.hres.ca. Retrieved 5 June 2022.
- ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
- ^ "Pifeltro 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". Medicines.org.uk. Retrieved 1 October 2020.
- ^ "Pifeltro EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
- ^ "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.
- ^ "Delstrigo EPAR". European Medicines Agency (EMA). 4 August 2023.
You must be logged in to post a comment.